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Cutaneous T-cell lymphoma (CTCL) is a neoplasm of 
CD4 + T cells that includes mycosis fungoides and its 
leukemic variant, Sezary syndrome. The phenotype 
of CTCL cells and their predilection for localizing in 
the skin and regional lymph nodes indicate that 
CTCL is a neoplasm of mature, memory helper T 
cells belonging to the skin-associated lymphoid 
tissue. Experimental evidence suggests that the 
mechanisms of lymphocyte activation in CTCL may 
involve both T-cell receptor-dependent and -inde­
pendent pathways. Furthermore, recent studies of 
the consequences of this activation have yielded sev­
eral important findings. First, a dominant T-cell 
clone is generally present in CTCL specimens, in­
cluding the earliest histologically diagnosable cuta­
neous patch lesions. Second, some cases of apparent 
chronic dermatitis harbor dominant T-cell clones. 
Such cases, known as "clonal dermatitis," have been 
observed to develop into overt CTCL. This suggests 
BIOLOGIC CHARACTERISTICS OF CUTANEOUS T-CELL 
LYMPHOMA (CTCL) 
CTCL is a neoplasm of CD4 + T cells that includes mycosis 
fungoides and its leukemic variant, Sezary syndrome [1]. Mycosis 
fungoides patients classically present with flat cutaneous patches or 
infiltrated cutaneous plaques. Subsequently, there is progression to 
cutaneous tumors, lymph node involvement, and ultimately vis­
ceral disease. Sezary syndrome patients present with erythroderma, 
lymphadenopathy, and leukemia. Their overall clinical course is 
more aggressive than that of mycosis fungoides patients. Ulti­
mately, some patients undergo "transformation" of their CTCL 
into high-grade large-cell lymphoma [2]. This is a poor prognostic 
sign with a median survival of only 1-2 years. CTCL tumor cells 
characteristically express CD2, CD3, CD4, CDS, CD4SRO, the 
cutaneous lymphocyte-associated antigen, and the a{3 heterodimer 
of the T-cell receptor (TCR) [1,3,4]. This immunophenotype of 
CTCL cells and their predilection for localizing in the skin and 
regional lymph nodes indicate that CTCL is a neoplasm of mature, 
memory helper T cells belonging to the skin-associated lymphoid 
tissue [1,3,5]. As such, CTCL is a tumor of cells that have the innate 
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tumor-infiltrating lymphocytes. 
that patients with clonal dermatitis may be at in­
creased risk for subsequent CTCL. Third, diseases 
associated with CTCL, such as lymphomatoid papu­
losis, large-cell lymphoma, and Hodgkin disease, arise 
as subclones of the original CTCL tumor and thereby 
share its clone-specific T-cell receptor gene rearrange­
ments. Development of these secondary lymphoprolif­
erative disorders appears to involve somatic mutations 
leading to deregulation of lymphoid activation/prolif­
eration pathways. Fourth, CDS+ tumor-infiltrating 
lymphocytes present within lesions of CD4 + CTCL 
express a phenotype consistent with activated, major 
histocompatibility complex-restricted, cytotoxic T-cell 
differentiation. They tend to be more plentiful in early­
stage disease and their proportion appears to correlate 
positively with improved survival, suggesting that they 
may exert an anti-tumor host response. Key words: T-cell 
receptor/mycosis iungoides/Sezary syndrome/molecular biology. 
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ability to traffic between the skin and regional lymph nodes. This 
probably accounts for the multifocality of skin lesions in early 
disease and obviates the question of whether CTCL is a systemic 
disease from its inception. In addition, the CD4SRO+ memory 
phenotype of CTCL suggests that, before their neoplastic transfor­
mation, CTCL tumor clones have already encountered the antigens 
for which their TCRs are specific [3]. However, the nature of these 
antigens remains to be eiucidated. In early CTCL, the proliferative 
rate is generally low [6]. This increases as disease progresses and 
becomes quite brisk in high-grade large-cell lymphomas, which 
include transformed CTCL [7]. It is apparent that the evolution of 
CTCL is accompanied by multiple somatic mutations because of 
the multiple karyotypic abnormalities that have been documented 
in tumor cells and because of the progressive dedifferentiation that 
accompanies disease progression [1,8]. 
MECHANISMS OF LYMPHOCYTE ACTIVATION IN CTCL 
Lymphocyte activation involves the transduction of extracellular 
signals resulting in the synthesis of ilew cellular proteins via the 
initiation of gene transcription. This leads to cell proliferation, 
phenotypic alteration, and the acquisition of novel functional 
capabilities by those lymphocyte clones able to recognize the 
relevant extracellular stimuli [9]. T-cell activation can occur in 
response to signaling through the TCR complex by specific 
antigens or superantigens [10,11]. Additional cell surface molecules 
also play a role in T-cell activation, as does the local cytokine milieu 
[9,11,12]. CD4+ helper T cells include subsets with different 
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cytokine profiles [13]. TH1 cells produce interleukin-2 (IL-2), 
which also serves as a growth factor for these cells. Similarly, TH2 
cells synthesize and respond to IL-4. Recent studies have shown 
that lesional T cells in Sezary syndrome express a TH2 cytokine 
profile [13,14], whereas those in mycosis fungoides exhibit pre­
dominantly a TH1 profile [14]. This suggests that these cytokines 
may be important for maintaining tumor cell activation and prolif­
eration in CTCL. In some cases, CTCL tumor cells can proliferate 
in response to superantigens [15] or exhibit enhanced activation 
through non-TCR cell surface molecules such as CD2, CD28, and 
CDw60 [16]. Other studies have shown CTCL tumor cells in close 
apposition to Langerbans cells, human leukocyte antigen (HLA)­
DR + keratinocytes, and dermal dendritic cells [1,17,18]. These 
cells are capable of serving as accessory cells for T-cell activation 
[11,17,18]. In fact, antigen-presenting cells obtained from CTCL 
lesions have exhibited an enhanced ability to activate autologous 
CD4 + T cells relative to similar cells obtained from uninvolved skin 
[18]. Despite these observations, further details concerning the 
mechanisms of T-cell activation in CTCL remain to be elucidated. 
As a result, the remainder of this discussion will focus primarily on 
the consequences, rather than the mechanisms, of lymphocyte 
activation in CTCL. 
CONSEQUENCES OF LYMPHOCYTE ACTIVATION 
IN CTCL 
Immunophenotypic studies have demonstrated that in addition to 
the tumor cell population, CTCL lesions also contain non-neoplas­
tic lymphocytes [19]. Therefore, analysis oflymphocyte activation 
in CTCL must distinguish between these cell populations. In this 
report, three consequences of lymphocyte activation in CTCt will 
be examined. The first focuses on the proliferation of tumor cell 
clones in early CTCL. The second focuses on the relation between 
CTCL and associated diseases that can develop in a subset of CTCL 
patients. The third focuses on reactive CD8+ T cells present within 
CD4 + CTCL lesions. 
Twnor Clone Proliferation in Early CTCL The results of 
Southern blot analysis of TCR gene rearrangements in CTCL first 
began to appear in the literature in the mid-1980s. It soon became 
apparent that, like most other T-cell neoplasms, advanced CTCL 
was a monoclonal T-cell disorder because Southern blot analysis of 
leukemic blood, involved lymph nodes, skin tumors, and thick plaques 
revealed dominant TCR gene rearrangements in patterns consistent 
with the presence of a single neoplastic T-cell clone (reviewed in 
[1,20-22]). In contrast, similar clonality analysis of earlier CTCL 
lesions such as flat patches and thin plaques was much more equivocal 
[1,20-22]. Although some cases exhibited evidence of dominant 
clonality, many cases appeared to be polyclonal by Southern blot 
analysis. However, it was not clear whether these cases were truly 
polyclonal or simply lacked a tumor clone density great enough to be 
detectable by Southern blot analysis, which has a sensitivity threshold 
of approximately 1% to 10% clonal cells depending on methodologic 
details and other technical factors [1,20-22]. 
The next advance along this line of investigation involved 
tumor-specific gene amplification techniques using the polymerase 
chain reaction (PCR). In these studies, tumor-specific oligonucle­
otide primers or probes were generated from advanced CTCL 
lesions and were used retrospectively to detect the same tumor cell 
population in earlier CTCL lesions from the same patient (reviewed 
in [20,21]). These studies demonstrated that tumor cells were 
present in early CTCL lesions and sometimes even in skin that 
appeared normal clinically but contained a sparse lymphoid infil­
trate histologically [20,21]. Although these studies provided impor­
tant new insights into the distribution of tumor cells in CTCL 
patients, they did not prospectively address the issue of tumor clone 
proliferation in early CTCL because they were retrospective studies 
dependent on the generation of tumor-specific oligonucleotides 
using information derived from the analysis of advanced CTCL 
lesions. What was needed was a method that allowed prospective 
analysis of tumor clone proliferation in early CTCL. 
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Figure 1. Southern blot analysis showing an absence of detectable 
TCR-13 gime rearrangements in mycosis fungoides cases that showed 
domiD,ant TCR-l' gene rearrangements by PCR/DGGE. Lane 1, nega­
tive Southern blot analysis of lesional skin from patch-type mycosis fungoides 
(TCR-J3 probe, BgnI digest). Lanes 2, 3, PCR/DGGE analysis of the same case 
as in lane 1 shows a V /,1-8 - pattern in morphologica11y normal peripheral blood 
(lane 2) and a V/,1-8+ pattern in the same skin specimen as in lane 1 (lane 3). 
Lane 4, negative Southern blot analysis oflesional skin from a mycosis fungoides 
tumor nodule (TCR-J3 probe, BgnI digest). Lanes 5, 6, PCRlDGGE analysis of 
the same specimen as in lane 4 shows V/,1-8+ and V-y'F patterns, respectively. 
The di1I"erence in the number of germline bands visible in lanes 1 and 4 is due 
to a polymorphism in the presence of Bglll restriction sites. Reprinted with 
permission from [22]. 
One such method involves the PCR-based amplification ofTCR-y 
gene rearrangements in genomic DNA extracted from CTCL skin 
lesions, followed by separation of the PCR products using denaturing 
gradient gel electrophoresis (PCRlDGGE) [22]. Titration studies have 
shown that one or more discrete bands will be visible using PCRI 
DGGE when a dominant T-cell clone constitutes approximately 0.1% 
or more of the total cell population (Fig 1). This results in a sensitivity 
threshold about 10-fold better than that with Southern blot analysis. 
Using this enhanced sensitivity clonality assay, dominant clonal 
TCR-'Y gene rearrangements were detected in about 90% of CTCL 
cases, including early cases with ouly patch or thin plaque lesions [22]. 
Direct comparison ofPCRlDGGE with Southern blot analysis for the 
detection of dominant clonality in early CTCL showed a false-negative 
rate of 71% for Southern blot analysis, compared with only 14% for 
PCRlDGGE [22]. This diJference in false-negative rates between 
PCRlDGGE and Southern blot analysis probably reflects the di1fer­
ence in CTCL tumor clone density in early versus late cases. As disease 
progresses, tumor clone expansion increases until tumor clone density 
becomes great enough to be consistently detectable by Southern blot 
analysis. The relative insensitivity of Southern blot analysis in early 
CTCL .also has been suggested by other studies involvmg PCR-based 
analysis of TCR-'Y gene rearrangements, which showed dominant 
clonality in a greater proportion of cases in the early patch phase than 
would have been expected by Southern blotting [23]. 
These results are significant for several reasons. First, they establish 
that, although CTCL tumors typically express the TCR-a/3 het­
erodimer on their cell surface [4], at least 90% contain rearranged 
TCR-'Y genes, thereby making them amenable to molecular biologic 
analysis using methods that detect TCR-'Y gene rearrangements. 
Second, they show that most cases of CTCL, including those with only 
early skin lesions, exhibit proliferation of dominant T-cell clones in 
their earliest recognizable clinical lesions. This implies that the activa­
tion pathways involved in dominant T-cell clonal selection and 
expansion are operant very early in the course of disease. 
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Third, these results imply that early CTCL resembles dermatitis 
in the sense that most of the cellular infiltrate is probably nonspe­
cifically recruited into lesions by a small vanguard of specific T 
cells. In dermatitis, such as allergic contact dermatitis, these van­
guard T cells are antigen specific. They are present at an estimated 
maximum density of 0.02% to 0.1% [24]. Because each antigen 
generally contains multiple unique epitopes, these antigen-specific 
T cells are probably composed of several dilferent T-cell clones, 
making the density of each clone well below 0.1% [23]. In early 
CTCL, these vanguard T cells may be the dominant tumor cell 
clone. It is a reflection of the well-dilferentiated nature of CTCL 
tumor cells that they, in turn, can be recruited into lesions of 
allergic contact dermatitis. In these lesions, which were induced in 
vivo by topical mechlorethamine, the tumor clone density was less 
than 0.1% but greater than 0.0001% of the total cell population. * 
These quantitative considerations have important implications 
for those trying to detect CTCL reactivity with monoclonal 
antibodies directed against specific Vf3 gene family proteins (re­
viewed in [23]). In the past, it was assumed that CTCL tumor cells 
were not reactive with a particular anti-Vf3 antibody if only a few 
percent of lesional T cells were stained. However, in early CTCL 
lesions, molecular biologic analysis suggests that the tumor clone 
density in many cases probably does not exceed a few percent of the 
total T-cell infiltrate [22,23]. This same principle is also likely to 
apply to CTCL in early relapse. 
The fourth interesting finding of PCRlDGGE analysis is that 
dominant clonality can be detected in some cases of apparent 
chronic dermatitis [22] . Presumably, these cases contain one or 
more clonal T-cell populations present at a density of greater than 
0.1% of total cells. These cases have been referred to as "clonal 
dermatitis." Their dominant T-cell clonality contrasts with poly­
clonality in a wide variety of non-neoplastic T-cell control skin 
lesions, such as the host response to epithelial tumors, psoriasis, 
pityriasis rubra pilaris, drug eruptions, arthropod reactions, and 
herpes zoster [22] . It is probable that patients with clonal dermatitis 
represent a subset that is at increased risk for the development of 
CTCL, because of the following: 1) the transition from clonal 
dermatitis to CTCL has been observed [22]; 2) previously diag­
nosed CTCL patients can relapse with histologically nonspecific 
clonal lesions that are indistinguishable from clonal dermatitis [22]; 
3) 0.1% exceeds the estimated maximal T-cell clonal density in 
inflammatory lesions such as allergic contact dermatitis [24]; and 
4) allergic contact dermatitis induced in CTCL patients lacks 
dominant clonality detectable at the 0.1% sensitivity level (see 
above). These observations are consistent with numerous anecdotal 
reports of CTCL evolving from chronic dermatitis [22]. They are 
also consistent with the increased risk for lymphoIl1a seen among 
other patients with clinically benign diseases containing dominant 
lymphoid clones, such as lymphomatoid papulosis, cutaneous 
lymphoid hyperplasia, other forms of extranodal lymphoid hyper­
plasia, angioirumunoblastic lymphadenopathy with dysproteinemia, 
and monoclonal gammopathy of uncertain significance, formerly 
known as benign monoclonal gammopathy [22]. 
Given these considerations, it is possible that patients classified as 
having clonal dermatitis may actually comprise as many as three 
different subsets: 1) truly benign, self-limited cases that have no 
malignant potential; 2) cases that are actually occult forms of fully 
developed CTCL that will eventually progress to overt CTCL; and 
3) cases that represent an intermediate, transitional point along a 
spectrum of clonal evolution linking chronic dermatitis to CTCL, 
i.e., cases that represent a dysfunction in the host's ability to control 
clonal expansion of T cells and that constitute a high-risk group 
from which CTCL can emerge direcdy through the progressive loss 
of proliferative control. It will be important to determine the rate at 
which patients with clonal dermatitis develop overt CTCL and, if it 
is significant, whether therapeutic intervention can decrease it. 
• Veelken H, Sklar] , Wood G: Presence of malignant T cells in lesions 
of allergic contact dermatitis developing in patients with cutaneous T cell 
lymphoma (abstr). Immunobiologl' 186:152,1992. 
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Figure 2. One- and two-clone models for the origin of large-cell 
lymphoma (LCL) in mycosis fungoides patients undergoing trans­
formation. Available evidence indicates that diseases associated with 
mycosis fungoides, such as large-cell lymphoma, arise as subclones of the 
original tumor (right) rather than as two independent T-cell clones (Itift). The 
T-cell clones share identical TCR gene rearrangements. Reprinted with 
permission from [2]. 
CTCL and Associated Diseases CTCL patients are at in­
creased risk for the development of other lymphoproliferative 
disorders including lymphomatoid papulosis, large-cell lymphoma, 
and Hodgkin disease [1]. The development of large-cell lymphoma 
in CTCL patients is known as the "transformation" of CTCL into 
large-cell lymphoma [2]. We have only recently begun to under­
stand the reasons for the association between these diseases and 
CTCL. Clonality studies of these disorders arising in CTCL patients 
have shown tumor-specific TCR gene rearrangements identical to 
those in the original CTCL tumor. This indicates that these 
disorders develop as sub clones of the original CTCL tumor clone 
(Fig 2). This clonal relation has been shown for CTCL in associ­
ation with lymphomatoid papulosis, Hodgkin disease, and large­
cell lymphoma [25]; for CTCL in association with large-cell 
lymphoma [2]; and for lymphomatoid papulosis in association with 
large-cell lymphoma or CTCL. t 
It is interesting that all three of these CTCL-associated disorders 
are characterized by the prominent expression of activation anti­
gens such as HLA-DR, CD25 (IL-2 receptor), and CD30 [1,2,25]. 
In contrast, CD30 is not expressed in CTCL, whereas CD25 and 
HLA-DR expression is highly variable [1]. Because clonality studies 
have shown that CTCL-associated lymphoproliferative disorders 
are actually subclones of the original CTCL tumor, these pheno­
typic dilferences in activation antigen expression suggest an associ­
ation between subclone development and lymphocyte activation 
pathways. 
Two recent findings may be relevant in this context. First, 
comparative studies were performed on CD30+ cell lines derived 
before and after CD30+ tumor progression in a patient who 
presented with CD30+ lymphomatoid papulosis and progressed to 
CD30+ anaplastic large-cell lymphoma after also developing 
Hodgkin disease and CTCL in the interim [26]. There was a loss of 
expression of receptors for transforming growth factor (TGF)-f3 in 
the cell line derived after tumor progression. TGF-f3 is a multifunc­
tional cytokine that can inhibit the proliferation of many cell types, 
including activated lymphocytes. This suggests that somatic muta­
tions leading to loss of TGF-f3 receptors may allow some lympho-
t Wood GS, Crooks CF. UIner AZ: Lymphomatoid papulosis and 
associated cutaneous lymphoproliferative disorders exhibit a common 
clonal origin.] Invest Derm4toll05:51-55, 1995. 
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Table I. Actuarial S-Year Survival ofCTCL Patients According to T Stage and Percentage ofLesional CDS+ TIL 
Lesional CD8+ TIL T1 (N = 24) T2 (N = 23) 
:515% 86% 67% 
<==20% 100% 100% 
P Value (Gehan) 0.03 0.3 
mas to escape down-regulation of lymphocyte activation signals. 
Although its functional significance is not known at present, a t(8;9) 
chromosomal translocation has also been described in both of these 
tumor cell lines, as well as numerous additional chromosomal 
abnormalities in the cell line after tumor progression [26]. Dimin­
ished expression ofTGF-� receptors has also been documented in 
other forms of T-cell neoplasia, including a cell line derived from 
the SS variant of CTCL [26]. 
A second important finding comes from studies of CD30+ 
anaplastic large-cell lymphomas of T-cell lineage. These tumors 
have shown a high prevalence of a t(2;5) (p2J;qJS) chromosomal 
translocation [27]. The two genes affected by this translocation are 
the nucleophosmin (a nucleolar phosphoprotein) gene on chromo­
some 5 and the anaplastic lymphoma kinase (ALK) gene on 
chromosome 2. Chimeric transcripts, whose production is con­
trolled by the nucleophosmin promoter, encode a fusion protein 
containing the amino terminus of nucleophosmin attached to the 
catalytic domain of ALK. Nucleotide sequence analysis indicates 
that this catalytic domain is similar to the insulin receptor subfiunily 
of protein tyrosine kinases, which includes leukocyte tyrosine 
kinase. ALK has not been detected in normal hematopoietic cells. 
Therefore, deregulation of ALK activity caused by the t(2;S) 
translocation may contribute to activation and malignant transfor­
mation in T cells bearing this somatic mutation. 
CDS+ T Cells in CD4+ CTCL Almost all cases of CTCL are 
neoplasms of CD4 + T cells. Nevertheless, lesional infiltrates typi­
cally contain an admixture of various non-neoplastic lymphoid 
cells, including CD8+ tumor-infiltrating lymphocytes (TIL) [1]. 
The role of these cells in CTCL remains to be fully elucidated; 
however, studies using one- and two-color immunohistology as 
well as in situ hybridization have shown that the majority of these 
CDS+ TIL express CD3 and mA-DR but lack CDllb, CD16, 
CDS6, and CDS7 [19,2S]. This phenotype is consistent with 
activated major histocompatibility complex (MHC)-restricted cy­
totoxic T-cell dilfurentiation. Further support for this interpretation 
came from studies of factors present in the cytoplasmic granules of 
cytolytic T cells and natural killer cells. These studies demonstrated 
that many of the CDS+ TIL in CTCL expressed TIA-l, an 
RNA-binding protein that can induce nuclear DNA fragmentation 
and may be the cytolytic granule factor responsible for causing 
apoptosis in the targets of cytotoxic T cells [19]. In addition, a small 
proportion of the CD8+ TIL in CTCL expressed granzyme A, a 
neutral serine protease found in cytolytic granules [28,29]. 
The presence of phenotypically defined, activated, MHC-re­
stricted cytotoxic T cells within CTCL lesions is not a unique 
situation. Phenotypically similar cells have been described in reac­
tive lymphoid tissues, allograft rejection, experimental choriomen-
T3 (N = 18) T4 (N = 13) All (N = 78) 
25% 0% 46% 
67% 0% 85% 
0.02 0.7 <0.01 
ingitis, squamous cell carcinomas, human immunodeficiency virus­
infected lymphoid tissues, lymphomatoid papulosis, cutaneous 
lymphoid hyperplasia, and cutaneous B-cell lymphomas [19]. Phe­
notypic studies have not been able to address the antigen specificity 
of these CDS+ TIL in CTCL. It is possible that they are bystander 
cells, nonspecifically recruited into CTCL lesions, which pose no 
direct cytotoxic threat to tumor clones. Alternatively, it is possible 
that these CDS+ TIL constitute an anti-tumor host response. 
Support for this latter possibility came from other studies of CTCL 
that analyzed the proportion of CDS + TIL in relation to T stage of 
skin disease and survival. Tl represents patches and plaques 
confined to less than 10% of the body surface area. T2 represents 
more extensive patch/plaque disease. TJ equates to cutaneous 
tumor nodules; T4 signifies erythroderma [1]. These studies 
showed that CTCL patients with more limited T -stage skin disease 
tended to have a higher proportion of CDS+ TIL in their skin 
lesions compared with patients with more advanced T -stage dis­
ease.:!: Furthermore, within each T stage, patients with a larger 
proportion of CDS+ TIL had a better survival than those with 
fewer CDS+ TIL (Table I). 
Additional evidence for the importance of CD8+ host response 
in CTCL came from studies of patients treated with extracorporeal 
photophoresis. Those patients with normal levels of circulating 
reactive lymphoid cells including CD8+ T cells had a better 
response to therapy than those in whom these cells were depleted 
[30,31]. Finally, recent investigations have shown a predominantly 
THl cytokine milieu in mycosis fungoides and a TH2 cytokine 
milieu in SS [13,14,17,32]. TH1 cytokines, which include 1L-2 and 
interferon-y, promote the generation of cytotoxic T cells. In 
contrast, TH2 cytokines, which include 1L-4, IL-S, and 1L-10, 
suppress the generation of cytotoxic T cells. This might help 
explain the better survival of patients with mycosis fungoides 
compared with those with SS. In aggregate, these studies of 
phenotype, survival, and response to therapy provide important 
evidence for the presence of an activated, MHC-restricted cyto­
toxic T-cell host response directed against tumor cells in patients 
withCTCL. 
CONCLUSIONS 
The correlation of clinicopathologic and molecular biologic find­
ings allows each patient evaluated for possible CTCL to be placed 
into one of five categories: chronic dermatitis, clonal dermatitis, 
early CTCL, advanced CTCL, or transformed CTCL (Table 11). 
* Hoppe RT, Medeiros LJ, Warnke RA, Wood GS: CD8+ tumor­
infiltrating lymphocytes influence the long-tenn survival of patients with 
mycosis fungoides. J Am Acad DmIIato/32:448-453, 1995. 
Table D. Diseases Defined by Correlation of CHnicopathologic and Molecular Biologic Data 
Disease 
Chronic dennatitis 
Clonal dermatitis 
Early CTCL· 
Advanced CTCL' 
Transfonned CTCL 
Histopathology 
Dermatitis 
Dennatitis 
CTCL 
CTCL 
Large-cell lymphoma 
Q Approximate percentage relative to total nucleated cells in specimen. 
• Patches, thin plaques. 
< Thick plaques. tuman. involved lymph nodes/viscera, leukemic blood. 
Dominant Clonality" PCR/DGGE Southern Blot Analysis 
<0.1% 
0.1�1% + 
0.10/ .... 10% + -/+ 
>10% + + 
>50% + + 
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SALT 
Benign Epigenetic Events 
Reactive 
T-cell Somatic Mutations 
Chronic Clonal Early 
Dermatitis Dermatitis CTCL 
<0.1% 0.1-1% 0.1-10% 
Malignant 
• Neoplastic 
T-cell 
Advanced Transformed 
CTCL 
>10% 
CTCL 
>50% 
ACTIVATION 
Proliferation 
Clonal Density 
Figure 3. Model for the clonal evolution of CTCL. In this model, 
there is a stepwise progression from chronic dennatitis to advanced CTCL, 
mediated by a series of genetic and epigenetic events that lead to increased 
activation, proliferation, and clonal density as well as decreased dUferenti­
ation, abnonnal trafficking, and attenuated host response. SALT, skin­
associated lymphoid tissue. Percentages refer to clonal density. 
Available evidence is consistent with the view that these disease 
categories represent dilferent clinicopathologically defined regions 
along a stepwise spectrum of somatic mutation that ultimately links 
reactive T cells in chronic dermatitis to neoplastic T cells in 
high-grade large-cell lymphoma (Fig 3). In this model, skin­
associated lymphoid tissue T cells are initially recruited to partici­
pate in a chronic inflammatory process. A dominant T-cell clone 
eventually emerges and persists via genetic and/or epigenetic 
events that remain to be elucidated. The latter might include TCR 
signaling by specific antigens or superantigens and/or alternative 
signaling pathways. This dominant clone then undergoes progres­
sive somatic mutation, resulting in the emergence of increasingly 
abnormal activation pathways, increased proliferative activity, and 
increased clonal density. This transformation is likely to involve 
multiple mutations, perhaps in some cases including the t(2;S) 
translocation or the TGF-f3 receptor alterations described above. It 
has also been suggested that T cells in CTCL patients may be 
"genotraumatic," i.e., inherently more susceptible to random 
somatic mutations [33]. In any event, as mutations accumulate in 
the CTCL clone, there is concomitant dedilferentiation, eventuat­
ing in phenotypic alterations, loss of normal skin-associated lym­
phoid tissue trafficking behavior, and an attenuation of the anti­
tumor host response . These biologic alterations result in the 
increasingly aggressive clinical behavior observed as disease 
progresses across the spectrum shown in Fig 3. This model is useful 
not only because of the light it sheds on the time course of tumor 
clone emergence in CTCL, but also because it suggests that 
therapeutic intervention in early-phase disease may prove more 
successful than later during a more biologically aggressive period in 
the clonal evolution of CTCL. Therapy in early-phase disease may 
also benefit from a greater anti-tumor host response . 
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